RHIZEN-PHARMACEUTICALS
Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced presentation of the interim results of a Phase I/II combination study of Tenalisib with Romidepsin for relapsed/refractory T-Cell Lymphoma patients at the upcoming 62nd American Society of Hematology (ASH) annual meeting and exposition, to be held virtually from December 5 – 8, 2020.
The poster presentation at ASH, 2020 includes interim data from a multi-center, open label, Phase I/II study in patients with T cell lymphoma (NCT03770000) with the objective of determining the MTD/optimal dose of Tenalisib given in combination with Romidepsin and assessing the preliminary efficacy of the combination. No dose limiting toxicities were reported and Tenalisib 800 mg BID plus Romidepsin 14 mg/m2 was determined to be the maximum tolerated dose for the expansion cohorts. Overall, the Tenalisib and Romidepsin combination was well tolerated across all patients (N=33) with no unexpected adverse events or increased frequency of adverse events previously reported for the individual agents.
As of the cut-off date (5th Nov 2020) for data analysis, seven PTCL patients had completed their first efficacy assessment (C3D1), of which four patients showed a complete response, one demonstrated a partial response and two had stable disease. The duration of response ranged from 1.4+ to 8.16+ months. Of the eleven CTCL patients who had completed their first efficacy assessment (C3D1), one patient showed a complete response, three demonstrated a partial response and five had stable disease. The duration of response ranged from 1.20+ to 10.6+ months.
Swaroop Vakkalanka, the company’s President and CEO stated, “We are extremely encouraged by the interim data being presented today which reinforces Tenalisib’s stellar safety and impressive efficacy when studied in combination with Romidepsin. Both PTCL and CTCL are difficult to treat indications and patients quickly run out of options, so we are excited with the preliminary results. We expect this study to eventually support a pivotal trial of the combination and we plan to approach the FDA when the full study results are available.
The Tenalisib poster session details at ASH 2020 are noted below:
- Poster Title: A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma (Publication Number: 1155)
- Session : 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster I
- Date : Saturday, December 5, 2020; 7:00 AM - 3:30 PM (Pacific Time)
- Presenter : Swaminathan P Iyer, MD, Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
About Tenalisib (RP 6530):
Tenalisib (RP6530) is a highly selective next generation orally active dual PI3K δ/γ inhibitor, which is in Phase 2 clinical development for hematological malignancies and solid tumors. Tenalisib has been granted US FDA Fast Track Designations for treatment of relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma (R/R PTCL and R/R CTCL), in addition to Orphan-Drug Designations for treatment of peripheral and cutaneous T-cell lymphoma (PTCL and CTCL).
About T-Cell Lymphomas:
T-Cell Lymphomas (TCL) are a group of cancers that originate in T-cells and develop in lymphoid tissues such as the lymph nodes and spleen, or outside of lymphoid tissues (i.e., gastrointestinal tract, liver, nasal cavity, skin, and others). TCL constitute ~7-15% of all NHL cases and can be generally classified based on their presentation, as indolent or aggressive.
Peripheral T-Cell Lymphoma (PTCL) describes a heterogeneous group of lymphoproliferative disorders arising from mature T-Cells and accounts for ~10% of all NHL cases. PTCL is an aggressive disease that most commonly presents in patients over the age of 60 and usually has a worse prognosis than diffuse large B cell lymphoma.
Cutaneous T-Cell Lymphoma (CTCL) describes a group of typically indolent lymphomas that appear on, and are most often confined to, the skin and accounts for ~3% of all NHL cases and usually affects adults. CTCL subtypes include the more common and indolent Mycosis Fungoides (MF), which is largely confined to the skin, and the less common but more severe Sezary Syndrome (SS) that affects both the skin and blood and has poor prognosis.
About Rhizen Pharmaceuticals S.A.:
Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel onco-therapeutics. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit https://www.rhizen.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201205005033/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Connectivity as Versatile as the Aircraft, Starlink High-Speed Internet Now Available for Cessna Caravan8.7.2025 16:00:00 CEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced an additional high-speed internet connectivity solution for the Cessna Citation Caravan following the Federal Aviation Administration’s (FAA) issuance of AeroMech’s Supplemental Type Certificate (STC) for Starlink high-speed internet connectivity. AeroMech’s STC utilizes Starlink’s constellation of Low Earth Orbit (LEO) satellites to provide more reliable connectivity over land, water and remote areas, where traditional in-flight Wi-Fi may not have service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708514119/en/ Textron Aviation announced an additional high-speed internet connectivity solution for the Cessna Citation Caravan following the Federal Aviation Administration’s (FAA) issuance of AeroMech’s Supplemental Type Certificate (STC) for Starlink high-speed internet connectivity. (Photo: Textron Aviation) “The Cessna Caravan is so versatile,
Rigaku Announces STAvesta, a Thermal Analyzer Tailor-made for Next-generation Material Development8.7.2025 16:00:00 CEST | Press release
Supports a wide range of users from novices to experts, serving a wide variety of needs Rigaku Corporation, a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”) has launched worldwide sales of STAvesta, a thermal analyzer that simultaneously measures a sample’s weight and change in calorific value during heating. STAvesta responds to needs in a wide array of fields where thermal analysis is required. It is expected to find use in a wide variety of material-analysis applications for the development of advanced features and complex materials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708207135/en/ STAvesta FlatBlank, a Revolutionary Auto-adjustment Feature, Dramatically Reduces Workload In conventional thermal analysis, baseline adjustment must be performed by hand before measurement can begin. This process can be time-consuming and frustrating, particu
Institutional Real Estate, Inc. Appoints Doris Holinaty as Managing Director – Global Markets8.7.2025 16:00:00 CEST | Press release
Institutional Real Estate, Inc. (“IREI”), the 38-year-old independent publisher of news and analysis for the institutional real estate investment community, today announced the appointment of Doris Holinaty as Managing Director – Global Markets. In this pivotal new role, Holinaty will be responsible for expanding IREI’s global footprint across its existing platforms and will spearhead business development for The Property Chronicle and The Green Chronicle, following IREI’s recent acquisition of Lyndon Publishing. Holinaty brings more than two decades of experience in selling and servicing publication and event sponsorships, including branding and strategic marketing for both print and digital communications media. “We are thrilled to welcome Doris to the IREI team. Her business values, experience and dynamic energy perfectly align with our values and our strategic vision to expand client servicing efforts in global markets,” said Tom Parker, Executive Vice President and Publisher of IR
Laserfiche Recognized as a 2025 Gartner® Peer Insights™ “Customers’ Choice” for Document Management8.7.2025 16:00:00 CEST | Press release
Laserfiche named a Customers’ Choice for six years in a row. Laserfiche — the leading SaaS provider of intelligent content management and business process automation — has been named a Customers’ Choice in the 2025 Gartner Peer Insights ‘Voice of the Customer’: Document Management report. This distinction is based on customer reviews. Vendors placed in the upper-right “Customers’ Choice” quadrant of the “Voice of the Customer” have scores that meet or exceed the market average for both axes (User Interest and Adoption, and Overall Experience). “We’re proud to be the only company recognized both as a Leader in the latest Magic QuadrantTM for Document Management and in the upper-right quadrant of the ‘Voice of the Customer’ report,” said Thomas Phelps IV, SVP of Corporate Strategy and Chief Information Officer at Laserfiche. “We believe both of these recognitions highlight our unwavering commitment to customer-centric innovation and delivering on our core value: ‘Drive Change, Deliver Re
Egon Zehnder Acquires Leading Asset and Wealth Management Boutique Firm The Prince Houston Group, Strengthening US Financial Services Practice8.7.2025 15:33:00 CEST | Press release
Egon Zehnder, the premier global leadership advisory and executive search firm, today announced the acquisition of The Prince Houston Group, a leading boutique executive search firm based in New York with a strong focus on Asset and Wealth Management. The Prince Houston Group serves a broad spectrum of outstanding clients across asset and wealth management, family offices, endowments and foundations, hedge funds, private equity funds, and insurance organizations. With a bespoke, high-integrity approach, their expertise will strengthen Egon Zehnder’s presence in the U.S. financial services sector. “This acquisition is part of our strategy to grow organically as well as through carefully selected expansion opportunities that align with our values and long-term vision,” said Michael Ensser, the Global Executive Chair of Egon Zehnder. “The Prince Houston Group’s depth of expertise in asset and wealth management and its bespoke approach will bolster our Financial Services Practice in the US
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom